Spark Therapeutics Conference Call February 20th

Spark Therapeutics will be hosting a conference call this Tuesday. For those interested in the business side of therapy, this is an interesting opportunity to observe. Find out more about Spark, and how to tune in below, or at the original source.

Spark Therapeutics is a fully integrated company. They focus on the discovery, delivery, and development of gene therapies. Specific disease targeted by the company include hemophilia, blindness, and a variety of neurodegenerative diseases. Three Spark programs exist in the clinical trial phase of development. Spark also developed the first FDA-approved gene therapy to treat a genetic disease in the United States. More information on Spark can be found at their website, Twitter, and LinkedIn.

The conference call will be hosted on Tuesday February 20th.

The call begins at 8:30 am EST. The primary topic will be 2017’s financial and corporate outcomes. This will include results and data up until the end of the previous business year for Spark (Dec. 31, 2017).

Interested parties can access the call by dialing (885) 851-4526 within the United States. International callers are directed to dial (720) 634-2901 instead. In either case, the passcode 9596288 will be required to enter the call.

The conference will also be available via the web. Spark provides live webcasting which can be found under the “Investors” section of their website.

Those unable to attend the call at its scheduled time need not worry. The conference will be recorded and available for one week after it is concluded. This recording will be accessible by dialing (855) 859-2056 within the United States or (404) 537-3406 Internationally. Callers must use the passcode 9596288 to access the recorded conference. Spark will also hos this content on their website.

Who: Spark Therapeutics
When: February 20th 2018, 8:00 AM EST
What: Conference Call Discussing Results of Previous Year
How: Call (885) 851-4526 US. Call (720) 634-2901 International. Passcode 9596288

Share this post